Personalis (PSNL) news
Recent news
Tempus AI, Inc.: Canaccord Genuity raises target price to $95 from $80
Canaccord Genuity has raised its price target for Tempus AI, Inc. (TEM) to $95 from $80, reflecting a more bullish outlook for the healthcare technology company. This adjustment aligns with recent developments, including the company’s first-quarter GAAP profitability, FDA approval for a key…
AInvest Wire · 1d agoPersonalis, Inc. - HSR waiting period expired October 2, 2026 for Tempus AI merger - SEC filing
The Hart-Scott-Rodino (HSR) waiting period related to Tempus AI’s proposed acquisition of Personalis, Inc. expired on October 2, 2026, according to a recent SEC filing. This development marks a key procedural milestone in the merger process, indicating that regulatory scrutiny under the HSR Act has…
AInvest Wire · 7d agoPersonalis, Inc.: BTIG cuts to neutral from buy
BTIG Research has revised its rating for Personalis, Inc. (NASDAQ: PSNL), downgrading the stock from "Buy" to "Neutral," while maintaining a price target of $16.25 . This adjustment reflects a reassessment of the company’s outlook amid mixed financial performance and evolving market dynamics.…
AInvest Wire · 7d agoPersonalis - new task order effective Sept 30, 2026, valued up to $18.30 mln - SEC filing
Personalis, Inc. (NASDAQ: PSNL) has announced a new task order effective September 30, 2026, valued up to $18.30 million, according to a recent SEC filing. The task order is part of the company’s ongoing efforts to expand its clinical testing services and strengthen its position in the precision…
AInvest Wire · Aug 20, 2026Personalis - on Aug 20, received new task order under its contract with U.S. Department of Veterans Affairs for VA MVP
Personalis, Inc. (Nasdaq: PSNL) has received a new task order under its contract with the U.S. Department of Veterans Affairs (VA) for the VA Million Veteran Program (VA MVP), with an approximate value of up to $31 million . This task order was issued following the decision to extend the existing…
AInvest Wire · Aug 20, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.